Center for the Studies of Addiction
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT02324725
This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests probing various aspects of personality, memory, reward processing and attention.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 4
Philadelphia, Pennsylvania, 19104, United States
This study is using blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) to examine the brain predictors of adherence and outcomes of opioid antagonist therapy. Opioid-dependent intravenous heroin users are offered up to 3 monthly injections of the extended-release naltrexone (XRNTX) contingent upon successful outpatient non-opioid detoxification, with an additional 4 weeks of follow up. Brain responses to heroin-related pictures are recorded using fMRI prior to the 1st XRNTX injection and approximately 2 weeks thereafter the 1st XRNTX injection. Primary clinical variables include the number of injections (maximum of 3) accepted by participants, change in self-reported craving for opioids after exposure to drug-related visual cues during the brain fMRI sessions, urine levels of ten commonly abused substances and self-report of cigarette use.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
Other names: Vivitrol ®
Time frame: 1 hour
Brain, behavioral and motivational (e.g. craving) response to audiovisual drug-related and control stimuli (images, smells and sounds) and to standard tasks of decision making, self-appraisal, response inhibition, social interaction and reward processing.
Time frame: 6 months
behavioral
Time frame: 6 months
Urine toxicology for methamphetamine, amphetamines, cannabis, cocaine, oxycodone, buprenophine, methadone, opioids, benzodiazepines and barbiturates.
Time frame: 3 months
Number of injections (maximum of 3) accepted by participants
Time frame: 2 hours
Change in self-reported craving for opioids after exposure to opioid-related visual cues during functional MRI sessions
University of Pennsylvania
Other
Biomarkers of Disease and Response to Treatment in Opioid Addiction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00249457
Behavior, Behavior, Addictive
Baltimore, Maryland, United States
View Trial DetailsNCT02774954
Amphetamine Dependence, Amphetamine-Related Disorders
Los Angeles, California, United States
View Trial DetailsNCT00476242
Chemically-Induced Disorders, Heroin Dependence
New York, United States
View Trial DetailsNCT00158288
Alcohol & Drug Use, Behavior Therapy
West Haven, Connecticut, United States
View Trial Details